Just a week after securing an historic US approval for its one-time hemophilia B treatment, Hemgenix (etranacogene dezaparvovec-drlb), Dutch gene therapy compan 30 November 2022
In a landmark regulatory first, Dutch gene therapy company uniQure (Nasdaq: QURE) has secured approval for its one-time hemophilia B treatment, Hemgenix (etrana 23 November 2022
A decade on from the founding of The Cell and Gene Therapy Catapult (CGT Catapult), the UK-based industry accelerator is celebrating its successes. 22 November 2022
While excitement about the potential of CRISPR/Cas9 gene editing remains high, a setback for a leading company using this technique shows it is no golden ticket 18 November 2022
Research from industry analyst GlobalData has identified challenges in the development of new CAR-T cell therapies for chronic lymphocytic leukemia (CLL). 17 November 2022
Japan’s Ono Pharmaceutical has exercised its option to an iPS cell-derived chimeric antigen receptor (CAR)-T cell therapy targeting human epidermal growth facto 8 November 2022
Shares in Sensorion, a French biotech that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, was trading 1 7 November 2022
Boston, USA-based pricing watchdog The Institute for Clinical and Economic Review (ICER) has published an evidence report on the comparative clinical effectiven 2 November 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.